• Csaba András Dézsi.
• Department of Cardiology, Petz Aladár County Teaching Hospital, Vasvári P. str. 2-4, Győr 9024, Hungary. Electronic address: dcsa62@gmail.com.
• Int. J. Cardiol. 2014 Dec 20; 177 (3): 748-53.

AbstractAngiotensin II receptor blockers (ARBs) are one of the most frequently used antihypertensive drugs with good tolerability and are indicated for treatment of many cardiovascular morbidity. Findings from clinical studies conducted in the past decade, suggest a possible relationship between some ARB-active substances, and certain malignancies cannot be excluded. Despite a lack of agreement, clinical results do not rule out the possibility that type 2 angiotensin II receptor stimulation during ARB therapy may also have unfavorable consequences, such as the development of certain malignancies. However, according to the current official position of FDA, the cardiovascular benefits of ARB therapy far outweigh the risks. Based on the limited information available, this review aims to provide medical practitioners with a clearer view on the balance of the benefits and risks of ARBs. Copyright © 2014. Published by Elsevier Ireland Ltd.

19 keywords...

hide…